Di seguito sono riportate le informazioni acquisite su VIR BIOTECHNOLOGY, INC., che non è ancora inclusa nel nostro perimetro di ricerca.

Per richiedere una valutazione di questa azienda e l'inserimento nel Ranking OpenCorporation o se hai dati ulteriori, diversi e più aggiornati di quanto pubblicato in questa scheda aziendale OpenCorporation, scrivi a info@opencorporation.org così che il nostro team possa tenerne conto.

Aggiornato il 28 maggio 2020

Descrizione attività
(disponibile solo in inglese)

Research and experimental development on biotechnology (NACE2 7211)

This company operates as a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. It conducts business from its registered head office located in South San Francisco, United States of America. The company was established in 2016.The company is taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions. It has an industry-leading management team, board of directors and scientific advisors with significant experience in immunology and infectious diseases, and with progressing product candidates from early stage research to clinical trials, regulatory approval and ultimately commercialization. The company's current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

  • VIR BIOTECHNOLOGY, INC.

  • United States of America (US)
  • Tipo di azienda: Corporate
  • Impresa controllante: N/D
  • Amministratore Delegato (CEO): Dr. Vicki L. Sato
  • Compenso Amministratore Delegato: N/D
  • Sito web: www.vir.bio

Parametri finanziari

Numero di dipendenti

229
206
N/D
N/D

Fatturato *

7,202
9,317
2,257
N/D

EBIT *

-158,428
-103,661
-67,37
N/D

EBITDA *

-154,408
-101,254
-66,99
N/D

* numeri espressi in milioni

  • RepRisk indicator (ultimo mese)*: N/D

Dialogo sociale

  • Transnational Corporate Agreement (TCA): N/D
  • Global Framework Agreement (GFA): N/D
  • Societas Europaea (SE): N/D
  • Bangladesh Accord: N/D

Comitati Aziendali Europei

  • CAE*: N/D

Standard e certificazioni

  • Global Compact: N/D
  • CDP (Carbon Disclosure Project): N/D
  • Modern Slavery Statement: N/D
  • Transparency Index: N/D
  • SA8000 Social Accountability: N/D
  • Bilancio Integrato: N/D
  • ISO26000: N/D
  • Linee Guida Ocse: N/D
  • Social Development Goals (SDGs): N/D

Certificazione Global Reporting Initiative*

  • Global Reporting Initiative standards: N/D
  • Global Reporting Initiative GRI G4: N/D

Altre dichiarative aziendali

  • Responsabilità sociale d'impresa:
    N/D
  • Accessibilità: N/D

Policy

  • Policy sulla formazione: N/D
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro dove opera l'azienda: N/D
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro lungo filiera: N/D
  • Policy sulla diversità: N/D

Dichiarazioni universali

Dichiarazioni e trattati riconosciuti dal paese in cui l'azienda ha la sede legale

  • Dichiarazione universale dei Diritti Umani:
  • Convenzione europea dei diritti dell'uomo (CEDU):
  • Carta dei Diritti Fondamentali dei Lavoratori CDFL (Carta di Strasburgo 1989):
  • Carta dei diritti fondamentali dell'Unione Europea CDF UE (Carta di Nizza 2000):
  • Trattato sul funzionamento dell'Unione europea TFUE:
  • Sede legale in un Paese OCSE:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Direttive applicate alle sedi nella UE 27

  • D. 80/987/EEC: N/D
  • D. 89/391/EEC: N/D
  • D. 98/59/EC: N/D
  • D. 2000/43/EC: N/D
  • D. 2000/78/EC: N/D
  • D. 2001/23/EC: N/D
  • D. 2001/86/EC del Consiglio: N/D
  • D. 2002/14/EC: N/D
  • D. 2002/73/EC: N/D
  • D. 2003/72/EC del Consiglio: N/D
  • D. 2005/56/EC del PE e del Consiglio: N/D
  • D. 2009/38/EC: N/D
  • D. 2004/25/EC: N/D
  • D. 2011/35/EU: N/D

Presenza nei principali ranking

  • Global 100 Most Sustainable Corporations: N/D
  • Global CSR Rep Trak 100: N/D
  • BrandZ Top 100 Most Valuable US Brands: N/D
  • The Worlds Best Multinational Workplaces: N/D
  • The Gartner Supply Chain Top 25: N/D
  • The Worlds Most Innovative Companies: N/D
  • The Diversity Inc Top 50 Companies: N/D
  • Best Global Websites: N/D
  • Green Ranking Global Top 500: N/D
  • Green Ranking Global Top 100: N/D

Ultime news su vir biotechnology, inc.

9 marzo 2020 - 12:00

These nine companies are working on coronavirus treatments or vaccines — here’s where things stand

The list includes Gilead Sciences Inc. and Moderna Inc. along with smaller biotechs

In the U.S., the companies that are initiating development have received funding from two organizations: the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. Some companies have received funding from Coalition for Epidemic Preparedness Innovations (CEPI), a global organization based in Oslo. Other companies are funding trials by themselves or through partnerships with other life sciences companies.